Merck & Co. Files 8-K: Director Changes, Compensation, Bylaws

Ticker: MRK · Form: 8-K · Filed: 2024-11-22T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-compensation, bylaws

Related Tickers: MRK

TL;DR

Merck's 8-K: New directors elected, exec pay tweaked, bylaws amended. Governance update.

AI Summary

On November 19, 2024, Merck & Co., Inc. filed an 8-K report detailing several key events. The company announced the election of new directors and changes in officer compensation arrangements. Additionally, Merck & Co., Inc. filed amendments to its articles of incorporation and bylaws, and provided financial statement exhibits.

Why It Matters

This filing indicates potential shifts in corporate governance and executive compensation, which could impact the company's strategic direction and investor relations.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance updates and financial disclosures, with no immediate negative financial implications apparent.

Key Players & Entities

FAQ

Who were the newly elected directors?

The filing indicates the election of new directors but does not name them in the provided text.

What specific changes were made to officer compensation arrangements?

The filing states that there were changes to compensatory arrangements of certain officers, but the specific details are not provided in this excerpt.

What were the key amendments to the articles of incorporation or bylaws?

The filing notes amendments to the articles of incorporation or bylaws, but the specific content of these amendments is not detailed in the provided text.

What financial statements and exhibits were filed?

The filing indicates that financial statements and exhibits were filed, but their specific content is not described in this excerpt.

What is Merck & Co., Inc.'s fiscal year end?

Merck & Co., Inc.'s fiscal year ends on December 31st.

From the Filing

0001104659-24-122027.txt : 20241122 0001104659-24-122027.hdr.sgml : 20241122 20241122142806 ACCESSION NUMBER: 0001104659-24-122027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241119 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241122 DATE AS OF CHANGE: 20241122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 241488930 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 8-K 1 tm2429161d1_8k.htm FORM 8-K false --12-31 0000310158 0000310158 2024-11-19 2024-11-19 0000310158 us-gaap:CommonStockMember 2024-11-19 2024-11-19 0000310158 mrk:Sec1.875NotesDue2026Member 2024-11-19 2024-11-19 0000310158 mrk:Sec3.250NotesDue2032Member 2024-11-19 2024-11-19 0000310158 mrk:Sec2.500NotesDue2034Member 2024-11-19 2024-11-19 0000310158 mrk:Sec1.375NotesDue2036Member 2024-11-19 2024-11-19 0000310158 mrk:Sec3.500NotesDue2037Member 2024-11-19 2024-11-19 0000310158 mrk:Sec3.700NotesDue2044Member 2024-11-19 2024-11-19 0000310158 mrk:Sec3.750NotesDue2054Member 2024-11-19 2024-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) November 22, 2024 ( November 19, 2024 )   Merck & Co., Inc. (Exact name of registrant as specified in its charter)   New Jersey (State or other jurisdiction of incorporation)   1-6571 (Commission File Number)   22-1918501 (I.R.S. Employer Identification No.)   126 East Lincoln Avenue , Rahway , NJ (Address of principal executive offices)   07065 (Zip Code)   (Registrant’s telephone number, including area code) ( 908 ) 740-4000   Not Applicable (Former name, former address and former fiscal year, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchan

View on Read The Filing